

Effect of the Application of Trial Inclusion Criteria on the Efficacy of Adalimumab Therapy in a Rheumatoid Arthritis Cohort

INGRID M. VISMAN, GEERTJE M. BARTELDIS, WOUTER OUWERKERK, ANITA C.J. RAVELLI, LINDA M. PEELEN, BEN A.C. DIJKMANS, MAARTEN BOERS, and MIKE T. NURMOHAMED

ABSTRACT. *Objective.* To evaluate the influence of inclusion criteria used in rheumatoid arthritis (RA) trials with adalimumab on clinical outcome and response.

Methods. The different inclusion criteria of published trials of adalimumab in RA were separately applied to a large prospective cohort of patients with RA treated with adalimumab (AdRA cohort), thereby mimicking patient selection for a clinical trial. Clinical response and outcome in the resulting 11 projection groups were compared using the 28-joint Disease Activity Score (DAS28) and time-averaged DAS28 as outcome measures of efficacy.

Results. Thirteen trials ($n = 54\text{--}799$) with 11 different sets of entry criteria were identified, resulting in 11 projection groups ($n = 22\text{--}168$). The DAS28 at baseline was similar in the original trial and each projection group based on this trial (5.1–6.4, total AdRA cohort 5.1). After 28 weeks, the efficacy varied substantially among the 11 projected groups (change from baseline DAS28: -1.65 to -2.65 , time-averaged DAS28 3.67–4.53). Expressed as outcome (DAS28 at 28 weeks), the efficacy was much more similar for almost all projection groups (3.5–4.0) and thus appeared to be mostly independent of disease activity at baseline.

Conclusion. We observed that different inclusion criteria for clinical trials can have a marked effect on the expected response, i.e., improvement from baseline. A novel finding is that final disease activity appeared much less dependent on initial disease activity. Our study suggests that for daily practice, one can assume that adalimumab treatment will on average result in a DAS28 between 3.5 and 4.0 after 28 weeks of treatment, regardless of baseline disease activity. (J Rheumatol First Release June 15 2011; doi:10.3899/jrheum.101283)

Key Indexing Terms:

RHEUMATOID ARTHRITIS ADALIMUMAB CLINICAL TRIALS DISEASE ACTIVITY

There have been many efforts to standardize the classification and clinical outcome of rheumatic diseases¹. Efficacy in clinical trials is measured with standardized disease activity scales based upon a core set of disease activity standards. The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) response criteria and the Disease Activity Score (DAS) response^{2,3,4,5,6,7} are widely used. Recently, more attention is being paid to minimal disease

activity state or remission as an important outcome⁸. Trials on the efficacy of adalimumab in patients with RA show different outcomes^{9,10}. These differences in efficacy between trials may be caused by differences in patients, geographic location, and ethnicity. Another important source of differences in outcome may be the use of different inclusion criteria¹¹.

Many different inclusion criteria are used in clinical trials on adalimumab in RA. However, the effect of inclusion criteria on clinical outcome and clinical response is not completely clear. Zink, *et al*¹² reported that patients in randomized controlled trials (RCT) are not the same as those seen in daily clinical practice and that clinical outcomes also differ between RCT and daily practice. Zink, *et al* compared characteristics of eligible versus ineligible patients in trials of various biologic agents and reported that patients ineligible for the trials benefit less from treatment than the eligible patients benefited in the original trials. In our study, we compare patients who would be eligible based on different sets of inclusion criteria, focusing on adalimumab trials only. In our cohort we mainly use the DAS28 as an outcome measure.

The objective of the current investigation is 2-fold. The first aim is to assess the influence of the use of different inclu-

From the Jan van Breemen Institute, Amsterdam; the Department of Medical Informatics, Academic Medical Centre, Amsterdam; the Julius Center for Health Sciences and Primary Care, UMC Utrecht; and the VU University Medical Center, Amsterdam, The Netherlands.

Supported by Abbott Laboratories.

I.M. Visman, MSc; G.M. Bartelds, MD; W. Ouwerkerk, MSc, Jan van Breemen Institute; A.C.J. Ravelli, PhD, Department of Medical Informatics, Academic Medical Centre; L.M. Peelen, PhD, Julius Center for Health Sciences and Primary Care, UMC Utrecht; B.A.C. Dijkmans, MD, PhD, Jan van Breemen Institute, VU University Medical Center; M. Boers, MD, PhD, VU University Medical Center; M.T. Nurmohamed, MD, PhD, Jan van Breemen Institute, VU University Medical Center.

Address correspondence to Dr. M.T. Nurmohamed, Jan van Breemen Instituut, Dr. Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands. E-mail: m.nurmohamed@janvanbreemen.nl

Accepted for publication April 5, 2011.

sion criteria on efficacy. This is done by “projecting” the inclusion criteria used in clinical trials on a cohort of patients with RA treated with adalimumab in daily clinical practice. Second, we compared the outcome of the clinical trials to the actual outcome in daily clinical practice by comparing the efficacy reported in the original trial with the efficacy found in the projection group using the same inclusion criteria.

MATERIALS AND METHODS

A literature search was performed using Medline and the Cochrane library. Articles reporting clinical trials on adalimumab treatment in patients with RA were selected from 1997 until September 2006. Search terms were “adalimumab,” “Humira,” “anti-tumour necrosis factor,” “rheumatoid arthritis,” and “RA”. Clinical outcome measurements had to include either a DAS/DAS28 score^{2,4,5,6}, EULAR response criteria, or an ACR response (ACR20, ACR50, ACR70, or ACR-N^{13,14}).

Articles were selected if the inclusion criteria for the study were clearly stated. If different trials from similar authors used identical inclusion criteria, those trials were considered 1 group.

The groups of inclusion criteria were sorted on strictness, ranging from light to strict. The strictness of the inclusion criteria is based upon an arbitrary scale determined by the effect of the separate variables on the DAS28 score and the ACR core set of disease activity measurements at baseline. Subsequently, 2 experienced rheumatologists decided on the order of the trials that were later classified as having light, medium, and strict inclusion criteria, based on the DAS28 score as well as the number of swollen and tender joints.

To evaluate the influence of different inclusion criteria on clinical outcome and response without the confounding effect of differences between study populations in clinical trials, the projection method was used¹¹. This method mimics the patient selection process by projecting the set of inclusion criteria onto a clinical practice cohort of a large outpatient clinic. This results in 1 projection group per set of inclusion criteria, containing the patients that would have been eligible for a trial using those criteria. This procedure is performed for all sets of inclusion criteria. Because the patients selected for each of the projection groups originate from the same general cohort, differences in outcome that are found between the projection groups is most likely caused by differences in inclusion criteria.

Our study is based on a prospective observational cohort of consecutive patients with RA who were treated with adalimumab therapy at the Department of Rheumatology of the Jan van Breemen Institute: the AdRA cohort. All patients with at least 28 weeks of followup were included. The patients had active disease at the time of inclusion, defined as a DAS28 > 3.2 despite earlier treatment with at least 2 disease-modifying antirheumatic drugs (DMARD), including methotrexate (MTX), at a dosage of 25 mg weekly or at the maximum tolerable dosage. All patients received adalimumab 40 mg subcutaneously every other week. Patients were excluded if they had contraindications for adalimumab use, as specified in the guidelines of the European Medicines Agency¹⁵. The medical ethics committee at the Slotervaart Hospital in Amsterdam, The Netherlands, approved of our study, which was carried out in compliance with the Helsinki Declaration.

We used 2 different outcome measures: the DAS28 and the DAS28 AUC (area under the curve). A third outcome measurement, the ACR response, is used to compare the original trial, the projected trial, and the total AdRA cohort if used in the published original trial.

Primary outcome measures are the change in DAS28 from 0 to 28 weeks and the DAS28 AUC. The DAS28 AUC is not often used. It measures the patient's cumulative disease activity over time

$$\left(\sum_{t=0}^{t=28} \text{DAS28} \right)$$

and is therefore used to identify differences in disease activity over time. The time-averaged DAS was calculated as the DAS28 AUC per week (DAS28

AUC/28) for every patient. The time-averaged DAS28 is the mean DAS during the 28 weeks of treatment for every patient. The mean time-averaged DAS is the mean of the DAS28 AUC per week in the projection group. The ACR response (ACR20, ACR50, ACR70) in the current study is calculated with 28 joints instead of the 66/68 joint count originally used, which is validated by van Gestel, *et al*^{6,7}.

Statistical analysis. The decrease in DAS28 score within each projection group from baseline to 28 weeks is analyzed by a paired sample t-test. An additional independent samples t-test was done to compare the decrease in DAS28 score of the patients in the AdRA cohort who had a higher DAS28 at baseline (DAS28 > 5.1) versus the other half, who had a lower DAS28 at baseline (DAS28 < 5.1).

For the comparisons between the projection groups it is important to realize that the projection groups overlap, i.e., they (partially) contain the same patients. Therefore, to assess the statistical significance of the difference in outcome between the projection groups, a nonparametric bootstrapping approach was used¹⁸. From the total AdRA cohort a random sample is drawn with replacement and the procedure of projecting the criteria is repeated using this sample. The projection groups thus obtained are used to calculate the difference in outcome measure. This sampling procedure is repeated *n* times, yielding a vector of differences of length *n*. Based on this vector, the mean difference is calculated, and a confidence interval is determined nonparametrically by calculating quantiles¹⁹. In our study, *n* was chosen to be 100,000. To reduce the risk of increasing type I errors due to multiple testing, we calculated a 99% CI to test for statistical significance instead of 95%. Further, we reduced the number of comparisons by choosing 3 trials (1 randomly selected trial within the strict criteria group of trials, 1 within the light criteria group, and 1 trial in the medium group) to be compared to each other and the AdRA cohort, instead of comparing all trials to each other.

In addition, to compare the efficacy reported in the trial with the efficacy obtained in clinical practice, we compared the outcome of the trial with the outcome in the projection group and the outcome in the total AdRA cohort. This is performed for 2 trials, 1 with light inclusion criteria and 2 with strict inclusion criteria. For the comparison, we used the efficacy outcome used in the original trial (DAS, DAS28, or ACR response).

RESULTS

Until September 2006, 13 eligible RA trials were published^{9,10,20,21,22,23,24,25,26,27,28,29,30}. This resulted in 11 different trial groups of inclusion criteria. One trial⁹ was excluded because it was a continuation of a primary trial already included and no changes in patient population were noted²⁶, and in another study the continued trial²⁹ included more patients than the original trial³⁰.

The main differences in inclusion criteria were based on differences in DAS score, tender joint count, swollen joint count, C-reactive protein, erythrocyte sedimentation rate, morning stiffness, previous DMARD used (including MTX and previous biological agents), rheumatoid factor, and erosions present.

In Table 1 the most important inclusion criteria of the different trials are shown. The trial groups are ordered according to the strictness of the inclusion criteria, increasing in strictness from left to right. All patients had RA according to the 1987 ACR criteria.

From 2004 to 2006, 237 patients were included in the AdRA cohort, and for our study all 168 patients were included who were treated for at least 28 weeks. The baseline characteristics of the population are presented in the first column of Table 2. The mean age of the patients was 56 years and there

Table 1. Different inclusion criteria by different rheumatoid arthritis (RA) trials.

Trial	Projection Group	N	DMARD	MTX	Inclusion Criteria			
					DAS28	SJC (66)/ TJC (68)	ESR, mm/h	CRP, mg/dl
Atzeni 2005 ²⁰	A	75						
Rau 2004 ²¹	B	54		x	≥ 3.2			
Barrera 2002 ^{22*}	C	198	3 wk washout TNF-α	2 wk washout	> 3.0			
Den Broeder 2002 ²³	D	74	3 wk washout		> 3.2			
Bennett 2005 ²⁴	E	70	Failure ≥ 2		> 5.1			
Weisman 2003 ^{25*}	F	60	3 wk washout	> 3 mo stable dose**		≥ 6/≥ 6	≥ 28	
Furst 2003 ¹⁰	G	636	Allowed	Failure		≥ 6/≥ 9 [‡]		
Weinblatt 2003 ^{9,26†}	H	271		≥ 6 mo stable dose**		≥ 6/≥ 9		
Keystone 2004 ^{27*††}	I	619	4 wk washout	≥ 3 mo stable dose**		≥ 6/≥ 9		> 1
				4 wk				
Breedveld 2006 ^{28††}	J	799	≤ 2			≥ 8/≥ 10	≥ 28	or ≥ 1.5
Van de Putte 2004 ^{29,30†}	K	544	Failure ≥ 1			≥ 10/≥ 12	≥ 28	or > 2

* Trials selected for pairwise comparison. † Double references. ‡ Both excluding distal interphalangeal joints. †† Rheumatoid factor or erosions were also a requirement, and for Breedveld also an RA duration > 3 years. ** Stable dose 12.5–25 mg/wk or ≥ 10 mg/wk in patients intolerant to MTX. MTX: methotrexate; DMARD: disease-modifying antirheumatic drugs; DAS28: 28-joint Disease Activity Score; SJC: swollen joint count; TJC: tender joint count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TNF: tumor necrosis factor.

Table 2. Baseline characteristics of the AdRA cohort and the 11 trial projection groups. Data are number (SD) unless otherwise indicated.

Projection Group	Trial	N	DAS28, t = 0 (SD)	Swollen Joints [†]	Tender Joints [†]	No. Previous DMARD
	AdRA cohort	168	5.13 (1.2)	7.9 (5.9)	7.5 (6.5)	3.2 (1.4)
A	Atzeni 2006 ²⁰	168	5.13 (1.2)	7.9 (5.9)	7.5 (6.5)	3.2 (1.4)
B	Rau 2004 ²¹	159	5.23 (1.2)	8.1 (6.0)	7.9 (6.5)	3.2 (1.5)
C*	Barrera 2002 ^{22*}	161	5.20 (1.2)	8.0 (6.0)	7.8 (6.4)	3.2 (1.4)
D	Den Broeder 2002 ²³	159	5.23 (1.2)	8.1 (6.0)	7.9 (6.5)	3.2 (1.5)
E	Bennett 2005 ²⁴	95	5.90 (1.0)	11.6 (6.0)	13.1 (6.5)	3.3 (1.5)
F*	Weisman 2003 ^{25*}	57	6.26 (1.0)	11.9 (5.9)	12.7 (5.8)	3.3 (1.5)
G	Furst 2003 ¹⁰	58	6.18 (1.0)	10.1 (6.4)	10.7 (6.6)	3.5 (1.5)
H	Weinblatt 2003 ^{9,26†}	39	6.37 (0.9)	11.8 (6.3)	11.2 (6.2)	2.8 (0.9)
I*	Keystone 2004 ^{27*}	36	6.27 (1.0)	12.9 (5.8)	12.2 (5.0)	3.7 (1.6)
J	Breedveld 2006 ²⁸	34	6.39 (1.0)	13.2 (6.2)	13.1 (5.5)	3.4 (1.4)
K	Van de Putte 2004 ^{29,30†}	22	6.38 (1.0)	15.9 (5.8)	15.3 (6.2)	3.5 (1.6)

* Trials selected for pairwise comparison of outcomes. † 0–28 joints. AdRA: large prospective cohort of patients with RA treated with adalimumab; DAS28: 28-joint Disease Activity Score; DMARD: disease-modifying antirheumatic drugs.

were more women than men in the cohort. The mean DAS28 at baseline is 5.1, which represents a high disease activity.

The projection of the 11 sets of inclusion criteria onto the AdRA cohort resulted in 11 projection groups (trial A to trial K). The baseline characteristics of the patients in those groups are presented in Table 2. All groups had similar percentages of women (78%–87%) and whites (78%–85%), and the mean disease duration (12–16 years) and mean age (56–58 years) were also similar.

As the inclusion criteria become more stringent, the number of patients eligible for inclusion decreases. We found that all 168 patients of the AdRA cohort would be eligible according to the criteria of trial A. When applying the strict criteria of projection group K, only 22 AdRA patients could be included.

At baseline, the DAS score differs from 5.20 in trial C (which has light inclusion criteria) to 6.26 in trial F (with medium criteria) to 6.38 in trial K, with the most stringent inclusion criteria.

Table 3 shows the efficacy outcomes of each of the 11 projection groups: the differences in DAS28 and time-averaged DAS28 from baseline until 28 weeks of treatment. The mean DAS28 baseline varies between 5.1 and 6.4, while the mean DAS28 at 28 weeks shows remarkably less variation, ranging from 3.5 to 4.0. The DAS28 AUC ranged from 103 to 127, and the time-averaged DAS28 ranged from 3.67 to 4.53. If we divide the AdRA cohort into 2 subgroups based on baseline DAS28 (cutpoint 5.1), those at or below the cutpoint (mean DAS28 4.1) decreased to 3.0 at 28 weeks, while those above

Table 3. Efficacy outcome measurements at 28 weeks of the trial “projection groups” projected on the AdRA cohort.

Outcomes Projection Groups	DAS28 T = 0 Weeks, mean (SD)	DAS28 T = 28 Weeks, mean (SD)	Decrease in DAS28, mean (SD) [†]	Percent of Patients in LDAS [‡] / Remission**	Time-average DAS28, mean (SD)
A	5.1 (1.2)	3.5 (1.5)	−1.65 (1.4)	43/27	3.67 (1.2)
B	5.2 (1.2)	3.5 (1.4)	−1.68 (1.4)	41/25 ^{††}	3.73 (1.2)
C*	5.2 (1.2)	3.5 (1.5)	−1.68 (1.4)	42/26 ^{††}	3.70 (1.2)
D	5.2 (1.2)	3.5 (1.4)	−1.68 (1.4)	41/25 ^{††}	3.73 (1.2)
E	5.9 (1.0)	3.9 (1.4)	−1.97 (1.5)	30 ^{††} /16 ^{††}	4.20 (1.1)
F*	6.3 (1.0)	3.9 (1.6)	−2.35 (1.5)	35/20	4.30 (1.2)
G	6.2 (1.0)	3.8 (1.6)	−2.45 (1.4)	39/25	4.24 (1.3)
H	6.4 (0.9)	4.0 (1.5)	−2.38 (1.5)	26 ^{††} /21	4.48 (1.2)
I*	6.3 (1.1)	3.7 (1.6)	−2.57 (1.4)	42/25	4.29 (1.2)
J	6.4 (1.0)	3.7 (1.6)	−2.65 (1.5)	41/29	4.36 (1.2)
K	6.4 (1.0)	4.0 (1.5)	−2.44 (1.4)	29/19	4.53 (1.1)

[†] p < 0.001 compared with baseline. ^{††} p < 0.05 compared with AdRA cohort. * Trials selected for pairwise comparison. [‡] LDAS, DAS28 at T = 28 weeks < 3.2. ** Remission, DAS28 at T = 28 weeks < 2.6. AdRA: large prospective cohort of patients with RA treated with adalimumab; DAS28: 28-joint Disease Activity Score; LDAS: low DAS.

the cutpoint (mean DAS28 6.1) decreased to 4.0. These results are similar to the results seen in the projection groups with comparable initial DAS28 score (Table 3).

For the statistical comparison of the outcomes in the projection groups we used the AdRA cohort and every third group thereafter (C, F, and I). We found that all patients in projection group F were also included in C (but not vice versa). When we compared the projection groups of trials F and I, 27 patients were eligible for F but not for I, 30 for both F and I, and 6 for I but not for F. This overlap necessitates the use of the bootstrapping approach. The groups F and I had a significantly higher DAS28 AUC than group C and the total AdRA cohort. The differences in DAS AUC between the projection groups F and I are not significant, which also holds for the difference between group C and the total AdRA cohort (Table 4). Hence, trial C and the total cohort can be considered as containing the less severely ill patients, while trials F and I seem to focus on the more severely ill patients with RA.

To illustrate differences between the efficacy outcomes observed in the trial and the outcome results obtained in daily clinical practice, we compared outcome of a light and strict inclusion criteria trial with the outcome in their projection groups and the outcome in the entire AdRA cohort (Figures 1 and 2). We used the outcome measure as used in the original trial as a basis for comparison.

Figure 1 shows the comparison between the original trial, that is, Barrera, *et al*²², the projection group C (the AdRA projection group based on the Barrera inclusion criteria), and the entire AdRA cohort. The inclusion criteria of this trial were classified as light. There is a small difference between the 3 curves in Figure 1. The original trial reaches a lower DAS28 over time than the projection group and the AdRA cohort. The lines of projection group C and the AdRA cohort are nearly identical, a finding in accord with the findings presented in Tables 2 and 4.

Figure 2 shows the comparison between the original trial (van de Putte, *et al*²⁹), the projection group K, and the AdRA

Table 4. Difference between projection groups C, F, and I and the AdRA cohort.

Comparison	Time-averaged DAS28 AUC	
	Difference Between Projection Groups*	99% CI of the Difference
AdRA cohort vs trial C	0.035	0.000 to 0.091
AdRA cohort vs trial F	0.631	0.296 to 1.007
AdRA cohort vs trial I	0.626	0.179 to 1.122
Trial C vs trial F	0.595	0.263 to 0.965
Trial C vs trial I	0.591	0.152 to 1.077
Trial F vs trial I	−0.004	−0.455 to 0.440

* Indicates mean value of the 100,000 differences in mean outcome measure between the groups obtained by the bootstrapping procedure. AdRA: large prospective cohort of patients with rheumatoid arthritis treated with adalimumab; DAS28: 28-joint Disease Activity Score; AUC: area under the curve.




Figure 1. Changes in the 28-joint Disease Activity Score in the AdRA cohort (a large group of patients with rheumatoid arthritis who were treated with adalimumab), the projection group C (the AdRA projection group based on the Barrera, *et al*, inclusion criteria), and the original Barrera 2002 trial²².

cohort. In contrast to the previous one, this trial used strict inclusion criteria. Figure 2 shows that the ACR20, 50, and 70 values over time of projection group K are much higher than in the original trial and in the total AdRA cohort.

DISCUSSION

Our simulation study shows that different levels of initial disease activity used as inclusion criteria lead to different levels of clinical response, i.e., improvement of DAS28 from baseline. A novel finding is the effect of adalimumab expressed as outcome, i.e., final disease activity appeared mostly independent of initial disease activity. Thus the differences in DAS28 improvement can mostly be attributed to differences in DAS28 scores at the start of treatment.

Further, there might also be differences between the outcome of the original trial, the outcome of projection of that trial in the AdRA cohort, and the whole AdRA cohort (Figures 1 and 2), which appear to depend on the strictness of the inclusion criteria. However, the statistical significance of these differences could not be assessed because we did not have detailed patient information from the original trial. For the comparison we used the efficacy outcome from the original trial (DAS28 or ACR response). This comparison is valid because treatment is the same in the AdRA cohort, and thus in the projection group of the clinical trial and in the trials themselves.

A limitation of our study is that some projection groups, such as projection group K ($n = 22$), have a low number of patients. This may be an explanation of the large differences in Figure 2.

In most clinical trials, the ACR response is based on a 66/68-joint count. Since we based the ACR response on a 28-joint count, the percentage change in tender and swollen joint count more rapidly rises or falls with the increase or decrease




Figure 2. American College of Rheumatology (ACR) response in the AdRA cohort of patients with rheumatoid arthritis who were treated with adalimumab, projection group K (the AdRA projection group based on the van de Putte, *et al*, inclusion criteria), and the van de Putte 2004 trial²⁹.

of severity of illness by one joint, which results in a more rapid increase or decrease in ACR response. This could be another reason why the results of projection group K in Figure 2 are much higher than in the original trial.

Our study shows that different inclusion criteria for clinical trials can have a marked effect on the expected response, i.e., improvement from baseline. This may lead to greater or less clinical response of patients in daily clinical practice. However, the importance of this finding may diminish if our results can be confirmed that in the end, final disease activity appeared to be much less dependent on initial disease activity. Most patients reached a similar level of disease activity,

regardless of their initial disease activity. In this case the clinician could turn to (or calculate) the end result of clinical studies to aid treatment decisions in daily clinical practice.

This novel finding suggests that for daily practice one can assume that adalimumab treatment will, on average, result in a DAS28 between 3.5 and 4.0 after 28 weeks of treatment, regardless of baseline disease activity.

REFERENCES

- Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. *J Rheumatol* 1998;25:198-9.
- Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum* 1993;36:729-40.
- Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. *J Rheumatol Suppl* 1994 Sep;41:86-9.
- Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44-8.
- van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Ann Rheum Dis* 1990;49:916-20.
- van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. *Br J Rheumatol* 1996;35 Suppl 2:4-7.
- van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. *Arthritis Rheum* 1996;39:34-40.
- Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. *J Rheumatol* 2005;32:2016-24.
- Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Ann Rheum Dis* 2006;65:753-9.
- Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). *J Rheumatol* 2003;30:2563-71.
- Peelen L, de Keizer NF, Peek N, Bosman RJ, Scheffer GJ, de Jonge E. Influence of entry criteria on mortality risk and number of eligible patients in recent studies on severe sepsis. *Crit Care Med* 2005;33:2178-83.
- Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. *Arthritis Rheum* 2006;54:3399-407.
- Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38:727-35.
- Pincus T, Amara I, Koch GG. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. *Arthritis Rheum* 2005;52:1031-6.
- European Medicines Agency. [Internet. Accessed June 8, 2011.] Available from: www.emea.eu.int/humandocs/PDFs/EPAR/humira/H-481-PI-en.pdf 2006
- Reduced joint counts in rheumatoid arthritis clinical trials. American College of Rheumatology Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum* 1994;37:463-4.
- Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. *Arthritis Rheum* 1994;37:470-5.
- Efron B. The jackknife, the bootstrap and other resampling plans. CBMS-NSF regional conference series in applied mathematics. Philadelphia: Society for Industrial and Applied Mathematics; 1982.
- Peelen L, Peek N, De Keizer NF, de Jonge E. Investigating the effect of differences in entry criteria on trial populations: a method with an application in severe sepsis. *Stud Health Technol Inform* 2005;116:1004-9.
- Atzeni F, Sarzi-Puttini P, Dell'Acqua D, de Portu S, Cecchini G, Cruini C, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. *Arthritis Res Ther* 2005;8:R3.
- Rau R, Simianer S, van Riel PL, van de Putte LB, Kruger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. *Scand J Rheumatol* 2004;33:145-53.
- Barrera P, van der Maas A, van Ede AE, Kiemeny BA, Laan RF, van de Putte LB, et al. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. *Rheumatology* 2002;41:430-9.
- den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. *Ann Rheum Dis* 2002;61:311-8.
- Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. *Rheumatology* 2005;44:1026-31.
- Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clin Ther* 2003;25:1700-21.
- Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum* 2003;48:35-45.
- Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y,

- Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum* 2004;50:1400-11.
28. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 2006;54:26-37.
29. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Ann Rheum Dis* 2004;63:508-16.
30. van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. *Ann Rheum Dis* 2003;62:1168-77.